ANIP,CRDF Stock Price and Quote

Peers: AMGN REGN VRTX BIIB GILD ILMN BMRN INCY NBIX UTHR

| Held by: IJR VTI IWM VXF SPSM IWO IJT PJP SCHA SLYG

Index	RUT	P/E	48.91	EPS (ttm)	1.63	Insider Own	13.78%	Shs Outstand	22.46M	Perf Week	-0.31%
Market Cap	1.79B	Forward P/E	9.15	EPS next Y	8.71	Insider Trans	-12.49%	Shs Float	19.37M	Perf Month	-1.59%
Enterprise Value	2.15B	PEG	0.37	EPS next Q	2.00	Inst Own	90.90%	Short Float	15.20%	Perf Quarter	-11.62%
Income	34.14M	P/S	2.17	EPS this Y	45.19%	Inst Trans	-0.42%	Short Ratio	6.18	Perf Half Y	-2.12%
Sales	826.88M	P/B	3.54	EPS next Y	15.43%	ROA	2.65%	Short Interest	2.94M	Perf YTD	1.02%
Book/sh	22.51	P/C	6.60	EPS next 5Y	25.07%	ROE	7.83%	52W High	99.50 -19.85%	Perf Year	32.50%
Cash/sh	12.08	P/FCF	11.46	EPS past 3/5Y	32.54% -	ROIC	3.04%	52W Low	54.10 47.41%	Perf 3Y	76.40%
Dividend Est.	1.50 (1.88%)	EV/EBITDA	14.86	Sales past 3/5Y	41.66% 24.36%	Gross Margin	50.09%	Volatility	3.15% 3.98%	Perf 5Y	158.17%
Dividend TTM	-	EV/Sales	2.60	EPS Y/Y TTM	422.30%	Oper. Margin	6.46%	ATR (14)	2.84	Perf 10Y	140.06%
Dividend Ex-Date	-	Quick Ratio	2.04	Sales Y/Y TTM	48.87%	Profit Margin	4.13%	RSI (14)	44.01	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	2.58	EPS Q/Q	189.47%	SMA20	-3.38%	Beta	0.50	Target Price	110.50
Payout	-	Debt/Eq	1.25	Sales Q/Q	53.58%	SMA50	-2.49%	Rel Volume	0.69	Prev Close	81.84
Employees	897	LT Debt/Eq	1.22	Earnings	Nov 07 BMO	SMA200	0.73%	Avg Volume	476.15K	Price	79.75
IPO	May 12, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.25% 7.03%	Trades		Volume	125,674	Change	-2.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Initiated	H.C. Wainwright	Buy	$84
Mar-14-25	Initiated	Jefferies	Buy	$80
Mar-12-25	Initiated	JP Morgan	Overweight	$85
Dec-11-24	Initiated	Leerink Partners	Outperform	$80
Oct-11-24	Initiated	Piper Sandler	Overweight	$68
Mar-15-24	Initiated	CapitalOne	Overweight	$80
Aug-22-23	Reiterated	H.C. Wainwright	Buy	$60 → $73
Mar-01-23	Initiated	Guggenheim	Buy	$55
Sep-07-22	Initiated	H.C. Wainwright	Buy	$50
Nov-02-21	Initiated	Truist	Buy	$70
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform	$73 → $82
Oct-16-17	Reiterated	Canaccord Genuity	Buy	$60 → $66
Jul-31-17	Initiated	Canaccord Genuity	Buy	$60
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy	$68
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy	$54
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy	$67 → $60

Show Previous Ratings

Feb-06-26 09:40AM	Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? (Zacks)
Feb-03-26 09:40AM	Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year? (Zacks)
Jan-27-26 08:51AM	Implied Volatility Surging for ANI Pharmaceuticals Stock Options (Zacks)
Jan-20-26 11:30PM	3 Value Stocks with Questionable Fundamentals (StockStory)
Jan-16-26 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:52AM	Loading…
08:52AM	ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now? (Zacks)
Jan-15-26 08:32AM	ANIP Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-14-26 12:02AM	ANI Pharmaceuticals Targets $1B+ 2026 Revenue as Rare Disease Pivot Accelerates, Cortrophin Leads Growth (MarketBeat)
Jan-13-26 12:01PM	ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why (StockStory)
04:21AM	Strength Seen in ANI (ANIP): Can Its 10.6% Jump Turn into More Strength? (Zacks)
Jan-12-26 04:05PM	Why ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today (StockStory) +10.58%
11:15AM	Equity Indexes Recover Early Losses as Precious Metals Reach New Record Highs (Barchart)
09:57AM	Stocks Retreat on Concerns Over Fed Independence (Barchart)
06:50AM	ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities (GlobeNewswire)
Jan-06-26 04:15PM	ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
11:53AM	Loading…
11:53AM	ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH (Zacks)
11:47AM	Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? (Zacks)
11:44AM	ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now? (Zacks)
11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks)
10:19AM	INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma (Zacks)
Jan-05-26 10:58AM	Intellia Stock Declines Around 55% in 3 Months: Here's Why (Zacks)
10:28AM	Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026 (Zacks)
10:26AM	FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children (Zacks)
Jan-04-26 11:03PM	3 Reasons to Avoid ANIP and 1 Stock to Buy Instead (StockStory)
Jan-02-26 11:22AM	Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio (Zacks)
10:54AM	AXSM Up on FDA Priority Review to AXS-05 sNDA in Alzheimer's Agitation (Zacks)
10:22AM	Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism (Zacks)
09:53AM	Will ANIP's Rare Disease Franchise Maintain Momentum in 2026? (Zacks)
08:15AM	INSM Stock Up 78% in 6 Months: Here's What You Need to Know (Zacks)
Dec-31-25 02:42PM	Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months (Zacks)
01:04PM	Loading…
01:04PM	Why You Should Add Encompass Health to Your Portfolio Now (Zacks)
11:24AM	Here's Why You Should Retain Community Health Stock for Now (Zacks)
09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)
09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks)
07:36AM	VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains (Zacks)
Dec-30-25 07:58AM	Kyverna Therapeutics Stock Up 41% in a Month: Here's Why (Zacks)
Dec-29-25 09:53AM	Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? (Zacks)
09:50AM	MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? (Zacks)
Dec-24-25 11:05AM	AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label (Zacks)
Dec-23-25 10:21AM	JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis (Zacks)
03:13AM	AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised) (Zacks)
Dec-22-25 12:45PM	Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
11:46AM	BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B (Zacks)
10:25AM	AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use (Zacks)
08:10AM	3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 (Zacks)
Dec-19-25 12:17PM	Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates (Zacks)
10:10AM	MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab (Zacks)
Dec-18-25 10:51AM	SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag (Zacks)
07:59AM	INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset (Zacks)
03:43AM	Zacks Industry Outlook Arcutis, Amicus and ANI (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
10:29AM	GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment (Zacks)
09:47AM	RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know (Zacks)
08:43AM	FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug (Zacks)
Dec-16-25 10:43AM	AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Zacks)
10:41AM	SNY Stock Down on Double Trouble With Multiple Sclerosis Drug (Zacks)
10:10AM	KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data (Zacks)
09:55AM	CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike (Zacks)
Dec-15-25 10:49AM	FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer (Zacks)
10:27AM	GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU (Zacks)
09:40AM	Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? (Zacks)
Dec-12-25 10:08AM	GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea (Zacks)
Dec-11-25 11:03AM	GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer (Zacks)
10:30AM	Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III (Zacks)
10:18AM	Implied Volatility Surging for ANI Pharmaceuticals Stock Options (Zacks)
Dec-10-25 09:43AM	TEVA Files NDA With FDA for Olanzapine LAI for Schizophrenia (Zacks)
Dec-09-25 10:43AM	KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study (Zacks)
10:24AM	Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date (Zacks)
Dec-08-25 10:39AM	PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know (Zacks)
10:30AM	Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status (Zacks)
Dec-05-25 10:37AM	ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study (Zacks)
10:34AM	CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know (Zacks)
Dec-04-25 12:45PM	ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
10:29AM	BMY Gains on News of Continuation of Alzheimer's Disease Study (Zacks)
Dec-03-25 03:45PM	Ensign Group Expands Foothold in Three U.S. States With Facility Buyouts (Zacks)
12:41PM	Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case (Zacks)
Dec-02-25 02:21PM	REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD (Zacks)
02:20PM	BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business (Zacks)
06:50AM	ANI Pharmaceuticals Announces Formation of "FutureVision Advisory Council" to Help Strategically Guide Ophthalmology and Retina Franchise (GlobeNewswire)
Dec-01-25 06:50AM	ANI Pharmaceuticals Announces Board Transition (GlobeNewswire)
Nov-28-25 10:56AM	ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick? (Zacks)
09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-25-25 06:50AM	ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-21-25 09:06AM	Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth (Zacks)
08:04AM	Why 2025 is a Dynamic and Transformative Year for Collegium (Zacks)
Nov-19-25 09:35AM	ANI (ANIP) Loses 15% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-18-25 11:35PM	1 Russell 2000 Stock to Consider Right Now and 2 We Avoid (StockStory)
12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP) (Zacks)
12:00PM	ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-17-25 01:13PM	Molina Secures Deal From AHCA to Serve Florida's Medicaid Members (Zacks)
Nov-14-25 08:44AM	ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell? (Zacks)
07:36AM	Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
12:31AM	The 5 Most Interesting Analyst Questions From ANI Pharmaceuticals's Q3 Earnings Call (StockStory)
Nov-13-25 09:08AM	Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint (Zacks)
Nov-12-25 09:40AM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-11-25 10:33PM	Generic Pharmaceuticals Stocks Q3 Recap: Benchmarking ANI Pharmaceuticals (NASDAQ:ANIP) (StockStory)
04:05PM	ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - London (GlobeNewswire)
10:37AM	Editas Q3 Loss Narrower Than Expected, Revenues Increase Y/Y (Zacks)
Nov-08-25 12:31AM	ANIP Q3 Deep Dive: Rare Disease Momentum and Generics Expansion Drive Upgraded Outlook (StockStory)

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jan 13 '26	Sale	84.33	500	42,165	74,374	Jan 14 06:14 PM
Davis Krista	SVP, CHIEF HR OFFICER	Dec 18 '25	Sale	82.40	1,622	133,653	58,564	Dec 19 04:47 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Dec 12 '25	Sale	82.32	400	32,928	74,874	Dec 12 04:26 PM
TANNENBAUM RENEE P	Director	Dec 05 '25	Sale	81.15	1,800	146,070	25,157	Dec 09 06:09 PM
RENATE PLAWNER TANNENBAUM 2024	Director	Dec 05 '25	Proposed Sale	81.15	1,800	146,070		Dec 09 05:12 PM
Walsh Patrick D	Director	Nov 13 '25	Sale	86.88	8,643	750,904	61,405	Nov 17 06:01 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Nov 12 '25	Sale	89.07	14,642	1,304,163	158,584	Nov 14 04:30 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Nov 13 '25	Sale	88.00	94	8,272	158,490	Nov 14 04:30 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Nov 13 '25	Sale	87.27	400	34,908	75,274	Nov 14 04:26 PM
PATRICK WALSH	Director	Nov 13 '25	Proposed Sale	86.88	8,643	750,914		Nov 13 04:48 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Oct 13 '25	Sale	90.09	400	36,036	75,674	Oct 14 07:49 PM
Davis Krista	SVP, CHIEF HR OFFICER	Sep 19 '25	Sale	98.04	1,000	98,040	60,186	Sep 22 05:14 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Sep 12 '25	Sale	98.42	400	39,368	76,074	Sep 15 07:16 PM
Pera Antonio R	Director	Sep 03 '25	Sale	94.94	7,292	692,302	22,660	Sep 04 04:44 PM
ANTONIO R PERA	Director	Sep 03 '25	Proposed Sale	94.94	7,292	692,270		Sep 03 04:03 PM
Leonard Matthew J	Director	Aug 25 '25	Sale	90.62	2,528	229,087	6,864	Aug 26 06:19 PM
MATTHEW LEONARD	Director	Aug 25 '25	Proposed Sale	90.62	2,528	229,076		Aug 25 05:00 PM
Davis Krista	SVP, CHIEF HR OFFICER	Aug 22 '25	Sale	91.10	1,763	160,609	62,896	Aug 25 04:19 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 21 '25	Sale	90.44	52,988	4,792,235	431,920	Aug 22 06:10 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 20 '25	Sale	90.27	47,012	4,243,773	484,908	Aug 22 06:10 PM
Shanmugam Muthusamy	Officer	Aug 21 '25	Proposed Sale	90.44	52,988	4,792,058		Aug 21 04:26 PM
Shanmugam Muthusamy	Officer	Aug 20 '25	Proposed Sale	90.27	47,012	4,243,703		Aug 20 04:58 PM
Thoma Jeanne	Director	Aug 18 '25	Sale	89.15	21,540	1,920,370	23,405	Aug 20 04:42 PM
Pera Antonio R	Director	Aug 20 '25	Sale	89.73	5,421	486,426	29,952	Aug 20 04:41 PM
ANTONIO R PERA	Director	Aug 20 '25	Proposed Sale	89.73	5,421	486,407		Aug 20 04:02 PM
JEANNE THOMA	Director	Aug 18 '25	Proposed Sale	88.87	14,675	1,304,170		Aug 19 05:47 PM
Leonard Matthew J	Director	Aug 18 '25	Sale	88.17	6,937	611,635	9,392	Aug 18 05:23 PM
Walsh Patrick D	Director	Aug 15 '25	Sale	89.05	9,000	801,450	70,048	Aug 18 04:34 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 15 '25	Sale	87.15	52,990	4,618,078	531,920	Aug 18 04:32 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Aug 14 '25	Sale	89.48	47,010	4,206,455	584,910	Aug 18 04:32 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Aug 15 '25	Sale	86.97	20,000	1,739,400	173,226	Aug 18 04:29 PM
JEANNE A THOMA	Director	Aug 18 '25	Proposed Sale	89.76	6,865	616,224		Aug 18 04:19 PM
MATTHEW LEONARD	Director	Aug 18 '25	Proposed Sale	88.17	6,937	611,644		Aug 18 04:18 PM
AMPERSAND 2020 LIMITED PARTNER	Director	Aug 18 '25	Proposed Sale	88.32	29,580	2,612,420		Aug 18 04:17 PM
PATRICK WALSH	Director	Aug 15 '25	Proposed Sale	89.05	9,000	801,450		Aug 15 04:27 PM
AMPERSAND 2020 LIMITED PARTNER	Director	Aug 15 '25	Proposed Sale	86.44	91,000	7,866,268		Aug 15 04:26 PM
Shanmugam Muthusamy	Officer	Aug 15 '25	Proposed Sale	87.15	52,990	4,618,064		Aug 15 04:04 PM
Rowland Thomas Andrew	SVP, HEAD - ESTABLISHED BRANDS	Aug 12 '25	Sale	85.71	4,975	426,407	40,794	Aug 14 05:53 PM
Lalwani Nikhil	PRESIDENT & CEO	Aug 12 '25	Sale	85.93	56,960	4,894,573	411,219	Aug 14 05:48 PM
Gutwerg Ori	SVP, GENERICS	Aug 12 '25	Sale	86.53	5,873	508,191	84,024	Aug 14 05:46 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Aug 13 '25	Sale	88.87	400	35,548	76,474	Aug 14 05:43 PM
CAREY STEPHEN P.	SVP & CFO	Aug 12 '25	Option Exercise	46.49	50,000	2,324,500	230,863	Aug 14 05:40 PM
CAREY STEPHEN P.	SVP & CFO	Aug 12 '25	Sale	86.07	50,000	4,303,500	180,863	Aug 14 05:40 PM
HAUGHEY THOMAS	Director	Aug 12 '25	Sale	85.93	19,341	1,661,972	36,521	Aug 14 05:38 PM
Shanmugam Muthusamy	Officer	Aug 14 '25	Proposed Sale	89.48	47,010	4,206,604		Aug 14 04:56 PM
NIKHIL S LALWANI	Officer	Aug 12 '25	Proposed Sale	85.93	56,960	4,894,823		Aug 12 06:04 PM
THOMAS HAUGHEY	Director	Aug 12 '25	Proposed Sale	85.93	19,341	1,662,048		Aug 12 05:16 PM
STEPHEN P CAREY	Officer	Aug 12 '25	Proposed Sale	86.07	50,000	4,303,590		Aug 12 04:15 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jul 14 '25	Sale	64.88	400	25,952	78,945	Jul 14 04:11 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jun 13 '25	Sale	61.37	400	24,548	79,345	Jun 16 05:24 PM
Gutwerg Ori	SVP, GENERICS	May 15 '25	Sale	60.07	881	52,922	89,897	May 16 04:57 PM
Mutz Christopher	HEAD OF RARE DISEASE	May 14 '25	Sale	60.45	4,000	241,800	107,317	May 15 08:10 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	May 13 '25	Sale	62.20	400	24,880	79,745	May 13 04:29 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 09 '25	Sale	76.83	700	53,781	631,920	May 13 04:21 PM
Shanmugam Muthusamy	Officer	May 09 '25	Proposed Sale	76.77	700	53,740		May 12 08:50 AM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Apr 14 '25	Sale	68.96	400	27,584	80,145	Apr 14 04:17 PM
Davis Krista	SVP, CHIEF HR OFFICER	Mar 19 '25	Sale	65.00	1,866	121,290	64,659	Mar 20 04:14 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Mar 13 '25	Sale	63.33	400	25,332	80,545	Mar 14 05:28 PM
Davis Krista	SVP, CHIEF HR OFFICER	Mar 07 '25	Sale	60.86	1,000	60,860	66,525	Mar 10 08:28 PM
Gutwerg Ori	SVP, GENERICS	Mar 05 '25	Option Exercise	31.49	300	9,447	99,476	Mar 07 04:09 PM
Gutwerg Ori	SVP, GENERICS	Mar 05 '25	Sale	60.00	5,384	323,049	94,092	Mar 07 04:09 PM
Davis Krista	SVP, CHIEF HR OFFICER	Feb 21 '25	Sale	60.20	1,000	60,200	68,624	Feb 24 04:33 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Feb 13 '25	Sale	59.54	400	23,816	83,478	Feb 18 08:12 PM

ANIP

ANI Pharmaceuticals Inc

CRDF

Cardiff Oncology Inc

ANIP

ANI Pharmaceuticals Inc

CRDF

Cardiff Oncology Inc

Upgrade your FINVIZ experience